Scientific

Event Publication Document
How much Target Expression is Enough? Learnings from advancing MP0712, a DLL3 Radio-DARPin for SCLC, into the clinic
Radio-DARPins: Expanding the Target and Indication Space for Targeted Alpha Therapy
MP0632, a logic-gated conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors co-expressing MSLN and EpCAM
DARPins as Ligands for Targeted Alpha Therapy: First-in-Human Experience with MP0712 and Opportunities for Next Radio-DARPin Candidates
Appropriate Targets for RLT? High selectivity vs high expression
Why Choose? DARPin Miniproteins as Isotope-Agnostic Vector for Targeted Alpha Therapies
[²¹²Pb] Pb-MP0712 in patients with small cell lung cancer and other Delta-like ligand 3-expressing solid tumors: A phase 1/2a study to assess safety, tolerability, and efficacy
Presentation by Dr. Ticiana Leal (Emory Winship Cancer Institute) of the MP0712 trial-in-progress
A phase 1/2a study to assess safety, tolerability, and efficacy of [²¹²Pb]Pb-MP0712 in patients with small cell lung cancer (SCLC) and other Delta-like ligand 3 (DLL3) expressing solid tumors
Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC)

Investors